Short-term efficacy and adverse reactions of mitomycin combined with gemcitabine in treatment of primary liver cancer

Objective: To study and compare the clinical effects of the combination of different interventional embolization chemotherapy and radiofrequency ablation in patients with primary liver cancer. Methods: In this paper, based on the target data validation of those 60 patients with primary liver cancer treated in the hospital during the period from May 2017 to May 2018, the double-blind method was used for the comparison between groups. Patients in the reference group were treated with the combination of cis-platinum interventional chemoembolization regimen and radiofrequency ablation, while those in the experimental group were treated with the combination of lobaplatin interventional chemoembolization regimen and radiofrequency ablation. Then, the efficacy of both groups was compared. Results: After the treatment, the clinically effective total value, the calculation value of adverse reactions, and the value of IgA, IgM, IgG and AFP of the experimental group were compared with those of the reference group. In addition, the value of IgA, IgM, IgG and AFP of both groups after and before the treatment were compared. The experimental results showed that the data was statistically significant (P<0.05). Conclusion: The combination of lobaplatin and cisplatin interventional embolization chemotherapy and radiofrequency ablation has some effects in patients with primary liver cancer, but the former one showed more significant effects.

Download Full-text

The Effect of Nano-Albumin Paclitaxel on the Early Postoperative Recurrence of Primary Liver Cancer

Journal of Nanoscience and Nanotechnology ◽

10.1166/jnn.2020.18710 ◽

2020 ◽

Vol 20 (12) ◽

pp. 7283-7288

Author(s):

Xinhong Wang ◽

Min Li ◽

Jing Wang ◽

Yihong Cao

Keyword(s):

Side Effects ◽

Liver Cancer ◽

Partial Remission ◽

Adverse Reactions ◽

Primary Liver Cancer ◽

Control Group ◽

Observation Group ◽

First Line ◽

Disease Progress ◽

Significant Difference

This study aimed at investigating the clinical effect and safety of albumin binding paclitaxel (Nab-P) for the first-line treatment of advanced primary liver cancer. Clinical data of 23 patients with primary liver cancer, who were treated in the first-line tumor treatment Department in the PLA General Hospital from May 2014 to December 2015, were analyzed retrospectively. The patients were divided into an observation group and a control group, according to their treatment plan. The patients in the observation group (12) received Nab-P treatment (5 cases of Nab-P combined with tegeor, 5 cases of Nab-P combined with capecitabine, and 2 cases of Nab-P single drug), and the patients in the control group (11) received gemcitabine combined with oxaliplatin. Each treatment cycle lasted for 21 days, and the treatment effect was evaluated once every two cycles, while the adverse reactions were assessed after every cycle. The survival rates of the different groups were compared using the chi-square test or the Fisher’s exact test, the Kaplan Meier survival curve, and the log rank test. Results from all patients were used to evaluate treatment efficacy and adverse reactions. In the observation group, there were 2 cases of partial remission, 7 cases of disease stability, and 3 cases of disease progress; in the control group, there were 2 cases of partial remission, 5 cases of disease stability, and 4 cases of disease progress. There was no significant difference in disease control rate between the two groups (75% vs. 64%, χ2 = 0.350, P > 0.05). There was no significant difference in the median progression free survival time between the two groups (5.1 (2.7–6.7) months versus 4.3 (2.5–54) months, χ2 =0.647, P > 0.05). No serious side effects were observed in any of the two groups. Among the observed side effects were some PLT toxicity and increased AST (Aspartate transaminase) incidence, which showed a statistically significant difference between the two groups (χ2 = 5.490, P = 0.036 for PLT; χ2 = 6.135, P = 0.027 for AST). The new Nab-P-based drug regimen has a good effect against primary liver cancer, and the side effects are tolerable. However, the sample size used in this study was small and further clinical studies using larger samples are required to verify the results.

Download Full-text